Table 1. Clinicopathological characteristics of the patients by study group.
Variables | Breast Cancer | Benign | Normal | ||||
---|---|---|---|---|---|---|---|
Premenopausal (N=47) | Menopausal (N=54) | Premenopausal (N=47) | Menopausal (N=54) | Premenopausal (N=47) | Menopausal (N=54) | ||
Age, median(range) | 40(24-50) | 56(46-78) | 40(26-50) | 56(47-74) | 41(24-53) | 56(46-78) | |
Family history of breast cancer | 3 | 4 | 1 | 3 | 1 | 2 | |
History of ovarian cancer | 0 | 0 | 0 | 1 | 0 | 0 | |
HT history | 0 | 0 | 0 | 0 | 0 | 0 | |
Prior biopsies | 19 | 22 | 16 | 21 | 0 | 0 | |
menstrual cycle | |||||||
week1 | 8 | NA | 8 | NA | 8 | NA | |
Week2 | 13 | NA | 13 | NA | 13 | NA | |
Week3 | 13 | NA | 13 | NA | 13 | NA | |
Week4 | 13 | NA | 13 | NA | 13 | NA | |
Type | |||||||
luminal A | 3 | 3 | NA | NA | NA | NA | |
luminal B | 31 | 34 | NA | NA | NA | NA | |
HER-2 overexpress | 12 | 12 | NA | NA | NA | NA | |
basal like | 1 | 5 | NA | NA | NA | NA |
NA, non-applicable; HER-2, human epidermal growth factor receptor 2, HT hormonal therapy